Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

An Study of Aripiprazole in the Treatment of Methamphetamine Dependence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01813656
Recruitment Status : Terminated (Aripiprazole arm had obvious adverse reactions,especially akathisia.)
First Posted : March 19, 2013
Last Update Posted : February 4, 2015
Information provided by (Responsible Party):
Wei Hao, Central South University

Brief Summary:
Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. Aripiprazole are Second generation antipsychotics,but have different pharmacological effects of neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among mehtamphetamine addicts.

Condition or disease Intervention/treatment Phase
Methamphetamine Dependence Drug: Aripiprazole Drug: placebo Phase 4

Detailed Description:
Methods:A Multiple-Center, Randomized, Double-Blind.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multiple-Center, Randomized, Double-Blind Study of Aripiprazole for Treatment of Methamphetamine Dependence
Study Start Date : September 2012
Actual Primary Completion Date : December 2013
Actual Study Completion Date : February 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Methamphetamine

Arm Intervention/treatment
Experimental: Aripiprazole
Aripiprazole arm,5mg/pill,10mg/day.last12weeks.
Drug: Aripiprazole
Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
Other Name: Aopai H20041507

Placebo Comparator: Sugar pill
placebo arm,5mg/pill,10mg/day,last12weeks
Drug: placebo
placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks

Primary Outcome Measures :
  1. abstinent time of Methamphetamine addict [ Time Frame: up to 3 months ]
    methamphetamine-positive urine test results,self-reports of substance use

Secondary Outcome Measures :
  1. number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: up to 3 months ]
    use Abnormal Involuntary Movement Scale ,Simpson-Angus Scale and Barnes akathisia Scale

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV) criteria for Methamphetamine dependence.
  2. Must sign a Information consent form.
  3. Required to provide detailed address and phone number

Exclusion Criteria:

  1. Serious organic disease.
  2. Suicide ideation or hurt others.
  3. Taking antipsychotic within two weeks before.
  4. drug allergy to Risperidone or Aripiprazole.
  5. pregnancy and breastfeeding women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01813656

Layout table for location information
China, Hunan
The Second Xiangya Hospital of Central University
Changsha, Hunan, China, 410011
Sponsors and Collaborators
Wei Hao
Layout table for investigator information
Study Director: Wei Hao, MD., Ph.D. Central South University

Layout table for additonal information
Responsible Party: Wei Hao, The Second Xiangya Hospital of Cental South University, Central South University Identifier: NCT01813656    
Other Study ID Numbers: 100000-068942
First Posted: March 19, 2013    Key Record Dates
Last Update Posted: February 4, 2015
Last Verified: February 2015
Keywords provided by Wei Hao, Central South University:
Methamphetamine-Associated Psychosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Dopamine D2 Receptor Antagonists
Dopamine Antagonists
Central Nervous System Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors